Biogen/IDEC Announce merger plans
Submitted by art on Tue, 2003-06-24 05:34.
Biogen and IDEC Pharmaceuticals, two companies looking for cures for cancer and autoimmune disorders, announced plans Monday to merge in a stock swap, the latest consolidation in the biotech industry.
IDEC, which is based in San Diego, makes the non-Hodgkin's lymphoma drug Rituxan. It had $404.2 million in sales last year. Biogen, with $1.15 billion in sales last year, is best known for its multiple sclerosis drug Avonex.


Hmmm